T
Teresa Klinowska
Researcher at AstraZeneca
Publications - 69
Citations - 4616
Teresa Klinowska is an academic researcher from AstraZeneca. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 23, co-authored 61 publications receiving 3733 citations. Previous affiliations of Teresa Klinowska include University of Manchester.
Papers
More filters
Journal ArticleDOI
Abstract P3-07-28: SERENA-1: Updated analyses from a Phase 1 study of the next generation oral selective estrogen receptor degrader camizestrant (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer
Nicholas C. Turner,Christos Vaklavas,Emiliano Calvo,Javier Garcia-Corbacho,Jason A. Incorvati,Manuel Ruiz Borrego,Chris Twelves,Anne C Armstrong,Begoña Bermejo,Erika Hamilton,Mafalda Melo Oliveira,Eva Ciruelos,Peter Kabos,Manesh R. Patel,Maria Borrell,Howard A. Burris,Bruno Henrique Rala de Paula,Alejandro Falcon,Cristina Hernando,Irene Moreno,Ciara S O'Brien,Elena Shagisultanova,Ivan Victoria Ruiz,Judy Wang,Meichen Wei,T Brier,Danielle Carroll,Carmela Ciardullo,Lise Gibbons,Itziar Irurzun-Arana,Tony Jack,Bistra Kirova,Teresa Klinowska,Justin P.O. Lindemann,Julie Maidment,Alastair Mathewson,Rhiannon Maudsley,Robert McEwen,Christopher J. Morrow,Andrew Sykes,Richard D. Baird +40 more
TL;DR: The SERENA-6 trial as discussed by the authors evaluated the safety and tolerability of the combination of camizestrant and abemaciclib in women with ER+/HER2− advanced breast cancer.
Book ChapterDOI
Analyzing how cell adhesion controls mammary gland function by transplantation of embryonic mammary tissue from knockout mice.
TL;DR: How transplantation of mammary tissue into recipient hosts can be used to extend the understanding of cell adhesion functions in developmental processes is described.
Journal ArticleDOI
Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: Exploratory analysis of the SERENA-2 phase 2 trial.
Mafalda Melo Oliveira,D.V. Pominchuk,Erika Hamilton,Yaroslav Kulyaba,T. Melkadze,Patrick Neven,Gia Nemsadze,T. T. Andabekov,Yuriy Semegen,Yevhen Hotko,Claudio Zamagni,Vladimir Vladimirov,Maxine Bennett,Carmela Ciardullo,Teresa Klinowska,Justin P.O. Lindemann,Robert McEwen,Christopher J. Morrow,Ekaterine Arkania +18 more
TL;DR: Oliveira et al. as mentioned in this paper compared Camizestrant, a next-generation oral selective estrogen receptor antagonist and degrader (ngSERD), to fulvestrant 500 mg (F) in postmenopausal women with advanced ER+, HER2˗ breast cancer with disease recurrence or progression after ≤1 endocrine therapy in the advanced setting in the Phase 2 randomized SERENA-2 study.
Journal ArticleDOI
Abstract PD10-04: PD10-04 Combination of the next generation oral SERD camizestrant (AZD9833) with CDK4/6 and mTOR/AKT inhibitors delivers robust efficacy in a broad range of ER+ breast tumors
Larissa S. Carnevalli,Susana Ros,Jelena Urosevic,Natalie Ison Cureton,Sophie Darcy,Mandy Lawson,SC Williamson,Pablo Morentin Gutierrez,A. Bashi,Jennifer I. Moss,Christopher J. Morrow,Barry Simon,Teresa Klinowska +12 more
TL;DR: Camizestrant (AZD9833) as mentioned in this paper is an oral selective estrogen receptor degraders (ngSERD) for the treatment of ER+BC which has demonstrated selective ERα degradation, pure ER antagonism and significant anti-tumor activity in ESR1 wild-type (ESR1wt) and mutant (ESr1m) tumors.